Seeking Alpha

Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox...

Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR)
Comments (5)
  • Wow. Hisun's pretty early on this.... they must have something on the Phase 3's to be that confident to put down that kind of call option.
    22 Jan 2013, 09:06 AM Reply Like
  • Yeah, right. This is peanuts and a weak attempt by management to generate some positive PR. Only the data knows.
    22 Jan 2013, 09:15 AM Reply Like
  • Exactly.
    22 Jan 2013, 09:19 AM Reply Like
  • There is no reason to think the data will not be positive as the research results to date have continually supported each phase , this agreement . Hisun will make the product and it will be used worldwide.
    22 Jan 2013, 09:53 AM Reply Like
  • Agree, sounds a lot like hype
    22 Jan 2013, 10:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)